Ribo Files European Trial for Novel siRNA Drug SR122

RecentNews.uk

Ribo has submitted a European clinical trial application for SR122.

The drug is a novel dual targeting siRNA designed for mixed and severe dyslipidemia.

The therapy aims to address complex lipid metabolism pathways in patients unresponsive to standard treatments.

Regulatory review will determine if human trials can proceed in Europe.

Will genetic siRNA therapies become the standard treatment for high cholesterol in the next decade?

Tap below to vote and see what others think.